Bicycle Therapeutics Overview
- Year Founded
-
2009
- Status
-
Public
- Employees
-
288
- Stock Symbol
-
BCYC
- Share Price
-
$3.35
- (As of Friday Closing)
Bicycle Therapeutics General Information
Description
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United Kingdom.
Contact Information
Website
www.bicycletherapeutics.comCorporate Office
- Blocks A & B Portway Building
- Granta Park, Great Abington
- Cambridge CB21 6GS
- England, United Kingdom
Corporate Office
- Blocks A & B Portway Building
- Granta Park, Great Abington
- Cambridge CB21 6GS
- England, United Kingdom
Bicycle Therapeutics Stock Performance
As of 13-Nov-2026, Bicycle Therapeutics’s stock price is $3.35. Its current market cap is $236M with 70.1M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $3.35 | $3.45 | $3.26 - $7.83 | $236M | 70.1M | 422K | -$2.03 |
Bicycle Therapeutics Financials Summary
As of 30-Sep-2026, Bicycle Therapeutics has a trailing 12-month revenue of $83.5M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | (237,817) | (151,457) | 86,869 | 240,584 |
| Revenue | 83,528 | 72,586 | 35,275 | 26,976 |
| EBITDA | (153,621) | (240,643) | (199,176) | (183,400) |
| Net Income | (141,790) | (218,960) | (169,031) | (180,664) |
| Total Assets | 567,179 | 717,597 | 956,868 | 595,344 |
| Total Debt | 14,184 | 16,852 | 9,493 | 44,956 |
Bicycle Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Bicycle Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Bicycle Therapeutics Comparisons
Industry
Financing
Details
Bicycle Therapeutics Competitors (41)
One of Bicycle Therapeutics’s 41 competitors is Agenus, a Formerly VC-backed company based in Lexington, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Agenus | Formerly VC-backed | Lexington, MA | ||||
| Rhythm Pharmaceuticals | Formerly VC-backed | Boston, MA | ||||
| Zealand Pharma | Formerly VC-backed | Soborg, Denmark | ||||
| Protagonist Therapeutics | Formerly VC-backed | Newark, CA | ||||
| Zymeworks | Formerly VC-backed | Vancouver, Canada |
Bicycle Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Bicycle Therapeutics Patents
Bicycle Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20260166163-A1 | Methods for treating cancer | Pending | 16-Nov-2021 | ||
| US-11180531-B2 | Bicyclic peptide ligands specific for nectin-4 | Active | 22-Jun-2018 | ||
| US-11453702-B2 | Bicyclic peptide ligands specific for nectin-4 | Active | 22-Jun-2018 | ||
| US-11912792-B2 | Bicyclic peptide ligands specific for nectin-4 | Active | 22-Jun-2018 | ||
| US-20190389906-A1 | Bicyclic peptide ligands specific for nectin-4 | Active | 22-Jun-2018 | C07K7/08 |
Bicycle Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Bicycle Therapeutics ESG
Risk Overview
Risk Rating
Updated July, 31, 2022
16.19 | Low Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,669
Rank
Percentile
Pharmaceuticals
Industry
of 895
Rank
Percentile
Biotechnology
Subindustry
of 396
Rank
Percentile
Bicycle Therapeutics FAQs
-
When was Bicycle Therapeutics founded?
Bicycle Therapeutics was founded in 2009.
-
Where is Bicycle Therapeutics headquartered?
Bicycle Therapeutics is headquartered in Cambridge, United Kingdom.
-
What is the size of Bicycle Therapeutics?
Bicycle Therapeutics has 288 total employees.
-
What industry is Bicycle Therapeutics in?
Bicycle Therapeutics’s primary industry is Drug Discovery.
-
Is Bicycle Therapeutics a private or public company?
Bicycle Therapeutics is a Public company.
-
What is Bicycle Therapeutics’s stock symbol?
The ticker symbol for Bicycle Therapeutics is BCYC.
-
What is the current stock price of Bicycle Therapeutics?
As of 13-Nov-2026 the stock price of Bicycle Therapeutics is $3.35.
-
What is the current market cap of Bicycle Therapeutics?
The current market capitalization of Bicycle Therapeutics is $236M.
-
What is Bicycle Therapeutics’s current revenue?
The trailing twelve month revenue for Bicycle Therapeutics is $83.5M.
-
Who are Bicycle Therapeutics’s competitors?
Agenus, Rhythm Pharmaceuticals, Zealand Pharma, Protagonist Therapeutics, and Zymeworks are some of the 41 competitors of Bicycle Therapeutics.
-
What is Bicycle Therapeutics’s annual earnings per share (EPS)?
Bicycle Therapeutics’s EPS for 12 months was -$2.03.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
